Moving Away from Spreadsheets: How to Know When It’s Time

July 23, 2018

The spreadsheet conundrum... Joe Smith, sales director for Great Start-Up Number 5 Billion and Thirty-One, puts on a blindfold and reaches out blindly for something, ANYTHING, to help him organize his team’s deals and commissions. He’s hopeful. He’s waiting. He knows he’ll come back with something. We’re talking metaphorically, of course. He’s not actually HOLDING a spreadsheet, he’s using Excel—because it’s the lowest hanging fruit. It’s free and easy to learn. And for a while, you know what? It works great. He can use VLOOKUPS and shortcuts to navigate. He can import booking results and activity metrics from Salesforce or his CRM. He can get so good at it that packaging complex algorithms becomes second nature.

Spotlight

Hookipa Biotech AG

Hookipa Biotech develops prophylactic and therapeutic vaccines for the prevention and treatments in oncology and for multiple infectious diseases. The company brings together experienced scientists, a diversified management team and a strong financial support to tackle the central challenges of cancer and immunology. Here at Hookipa our energy is sincere, we are motivated and together we can develop solutions for patients in need that don´t benefit from current therapies.

OTHER WHITEPAPERS
news image

BLOCKCHAIN ENABLED GENOME SECURITY FROM THE MOMENT IT IS SEQUENCED

whitePaper | June 8, 2022

Sequencing of human genomes is fast becoming an affordable technology for general consumer.

Read More
news image

The colors of life: an interdisciplinary artist-in-residence project to research fungal pigments as a gateway

whitePaper | January 10, 2022

Biological pigmentation is one of the most intriguing traits of many fungi. It holds signifcance to scientists, as a sign of biochemical metabolism and organism-environment interaction, and to artists, as the source of natural colors that capture the beauty of the microbial world.

Read More
news image

Long-term follow-up studies of cell and gene therapies

whitePaper | September 29, 2022

The market is experiencing a surge in the availability of cell and gene therapies (CGTs); it’s estimated that by 2025 as many as 20 will be introduced into the US each year.1,2

Read More
news image

A Playbook for Emerging Biotechs

whitePaper | March 24, 2023

The global biotech industry continues to witness growth with an estimated market size of nearly $300B, despite the current state of the funding environment

Read More
news image

A REVIEW OF THE RESEARCH TRENDS AND DEVELOPMENTS

whitePaper | May 9, 2022

In the last decade, there has been an encouraging shift in research, clinical development, and commercial activity to exploit the many biological roles of ribonucleic acid (RNA) for use in medicine.

Read More
news image

Producing therapeutic peptides using biotechnology

whitePaper | October 20, 2022

We began the project by working to the design of a recombinant bacterial strain selection of a strain capable of producing high concentrations of peptides.

Read More

Spotlight

Hookipa Biotech AG

Hookipa Biotech develops prophylactic and therapeutic vaccines for the prevention and treatments in oncology and for multiple infectious diseases. The company brings together experienced scientists, a diversified management team and a strong financial support to tackle the central challenges of cancer and immunology. Here at Hookipa our energy is sincere, we are motivated and together we can develop solutions for patients in need that don´t benefit from current therapies.

Events